Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Raman spectroscopy with surface-enhanced Raman scattering (SERS) through metal substrates is a highly precise bioimaging technique. Alternatively, recently discovered small molecules to enhance the Raman signal intensities through their self-stacking, termed stacking-induced intermolecular charge transfer-enhanced Raman scattering (SICTERS), offer ultrasensitive in vivo Raman imaging free of substrates. Molecular engineering to increase the SICTERS intensity and to tune photothermal conversion efficiency of these molecules is critical for furthering their biomedical application but not yet feasible. Here, by increasing the length of side chain and introducing the benzene ring to bis-thienyl-substituted benzobisthiadiazole, this study demonstrates an optimized molecule BBTPPRO that possesses both high SICTERS intensity and photothermal conversion efficiency (31.19%). The prepared BBTPPRO nanoparticles achieve intraoperative Raman image-guided photothermal therapy (PTT) of orthotopic mouse colon tumor. Overall, this report presents a molecular strategy combing the principle of SICTERS with the Jablonski diagram to design substrate-free Raman small molecules toward SICTERS-mediated photo-theranostic agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/advs.202505467 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mesoporous Zr MOFs regulated by linear ligand replacement strategy to achieve single Ru(bpy) molecule encapsulation for ratio ECL detection of miRNA-21.
Talanta
September 2025
College of Chemistry and Chemical Engineering, College of Materials Science and Engineering, Shandong Sino-Japanese Center for Collaborative Research of Carbon Nanomaterials, Qingdao Application Technology Innovation Center of Photoelectric Biosensing for Clinical Diagnosis and Treatment, Instrument
Rational optimization of the pore size and topology of porous nanocarriers is crucial for improving the loading amount of luminophore and enhancing electrochemiluminescence (ECL) performance. In this study, an equimolar linear ligand replacement strategy was employed to synthesize novel mesoporous metal-organic frameworks (MOFs) for encapsulating Ru(bpy) (Ru@Zr MOFs) under room temperature without an acid modulator. Ingenious ligand substitution allows precise control of pore size, enabling encapsulation at the single-molecule level within mesoporous cages.
View Article and Find Full Text PDFDiscovery of Potential GPRC5D Inhibitors through Virtual Screening and Molecular Dynamics Simulations.
ChemistryOpen
September 2025
Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China.
G protein-coupled receptor family C, group 5, member D (GPRC5D), a member of the G protein-coupled receptor (GPCR) family, has recently emerged as a promising target for immunotherapy in hematologic malignancies, particularly multiple myeloma. However, no systematic virtual screening studies have been conducted to identify small-molecule inhibitors targeting GPRC5D. To address this gap, a multistep computational screening strategy is developed that integrates Protein-Ligand Affinity prediction NETwork (PLANET), a GPU-accelerated version of AutoDock Vina (Vina-GPU), molecular mechanics/generalized born surface area (MM/GBSA), and an online tool for Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) property prediction (admetSAR 3.
View Article and Find Full Text PDFStructural Dynamics of Dengue Virus UTRs and Their Cyclization.
Biophys J
September 2025
Department of Chemistry and Biochemistry, Alberta RNA Research and Training Institute, University of Lethbridge, 4401 University Drive, Lethbridge, AB, T1K 3M4, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton T6G 2E1, Alberta, Canada; Department of Microbiology, Immunology
The dengue virus (DENV) poses a significant threat to human health, accounting for approximately 400 million infections each year. Its genome features a circular structure that facilitates replication through long-range RNA-RNA interactions, utilizing cyclization sequences located in the untranslated regions (UTRs). To gain new insights into the organization of the DENV genome, we purified the 5' and 3' UTRs of DENV in vitro and examined their structural and binding properties using various biophysical techniques combined with computational methods.
View Article and Find Full Text PDFRole of hydrogen sulfide in catalyzing the formation of NO-ferroheme.
Nitric Oxide
September 2025
Department of Physics, Wake Forest University, Winston-Salem, NC 27109, USA; Translational Science Center, Wake Forest University, Winston-Salem, NC 27109, USA. Electronic address:
We recently demonstrated a rapid reaction between labile ferric heme and nitric oxide (NO) in the presence of reduced glutathione (GSH) or other small thiols in a process called thiol-catalyzed reductive nitrosylation, yielding a novel signaling molecule, labile nitrosyl ferrous heme (NO-ferroheme), which we and others have shown can regulate vasodilation and platelet homeostasis. Red blood cells (RBCs) contain high concentrations of GSH, and NO can be generated in the RBC via nitrite reduction and/or RBC endothelial nitric oxide synthase (eNOS) so that NO-ferroheme could, in principle, be formed in the RBC. NO-ferroheme may also form in other cells and compartments, including in plasma, where another small and reactive thiol species, hydrogen sulfide (HS/HS), is also present and may catalyze NO-ferroheme formation akin to GSH.
View Article and Find Full Text PDFA concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT.
Bioorg Med Chem Lett
September 2025
Department of Radiology, The University of Chicago, Chicago, IL 60637, United States. Electronic address:
Murine double minute 2 (MDM2, also known as human double minute 2 or HDM2) is a negative regulator of the tumor suppressor protein p53 and is overexpressed in many cancers. Over the past two decades, substantial progress has been made in developing inhibitors of the MDM2-p53 interaction, thereby allowing the p53 protein to exert antitumor effects through cell apoptosis and cycle arrest. While there are currently no FDA-approved MDM2 inhibitors available, several small molecule MDM2 inhibitors and a stapled peptide inhibitor of the MDM2-p53 interaction are in clinical development.
View Article and Find Full Text PDF